Skuldtech is involved in the development of new diagnostics focused on personalized medicine applications. The company has already developed prototypes dedicated to the identification of specific biomarkers. 

Due to its expertise in genomics, in gene expression, in New Generation Sequencing (NGS) technologies, in bioinformatics and biostatistics, Skuldtech is currently involved in several developments concerning personalized medicine, companion diagnostics and patient stratification tests, which will enable stratifying and segmenting patients according to “typical profiles.”
Some of these innovative healthcare solutions are being subject to clinical validation.

For instance, Skuldtech has recently patented CMML biomarkers associated to a positive 4 years survival prognosis. These markers have been discovered through Digital Gene Expression analyses realized on several cell lines and blood samples, and have been validated in a clinical trial lead by the Nimes hospital through qRT-PCR technology. These CMML biomarkers will be validated in a large clinical trial in the next months

Moreover, Skuldtech has developed several prototypes focused on the (early) detection of emerging pathogens, such as: Dengue, Leishmania, etc.
These innovative healthcare prototypes are being subject to clinical validation.

If you need more information, please contact our business development department
(T: +33(0)467 419 748, Email: info@skuldtech.com).